%0 Generic
%A Bonanad, Clara
%A Garcia-Blas, Sergio
%A Llergo, Javier Torres
%A Fernandez-Olmo, Rosa
%A Diez-Villanueva, Pablo
%A Ariza-Sole, Albert
%A Martinez-Selles, Manuel
%A Raposeiras, Sergio
%A Ayesta, Ana
%A Bertomeu-Gonzalez, Vicente
%A Tarazona Santabalbina, Francisco
%A Facila, Lorenzo
%A Vivas, David
%A Gabaldon-Perez, Ana
%A Bodi, Vicente
%A Nunez, Julio
%A Cordero, Alberto
%T Direct Oral Anticoagulants versus Warfarin in Octogenarians with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis
%D 2021
%U https://hdl.handle.net/10668/26603
%X Direct oral anticoagulants (DOACs) have been demonstrated to be more effective and safer than vitamin-K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (AF). This meta-analysis aims to assess the effect of DOACS vs. VKA in patients >= 80 and AF. Primary endpoints were stroke or systemic embolism and all-cause death. Secondary endpoints included major bleeding, intracranial bleeding, and gastrointestinal bleeding. A random-effects model was selected due to significant heterogeneity. A total of 147,067 patients from 16 studies were included, 71,913 (48.90%) treated with DOACs and 75,154 with VKA (51.10%). The stroke rate was significantly lower in DOACs group compared with warfarin group (Relative risk (RR): 0.72; 95% confidence interval (CI): 0.63-0.82; p = 80 and AF. Primary endpoints were stroke or systemic embolism and all-cause death. Secondary endpoints included major bleeding, intracranial bleeding, and gastrointestinal bleeding. A random-effects model was selected due to significant heterogeneity. A total of 147,067 patients from 16 studies were included, 71,913 (48.90%) treated with DOACs and 75,154 with VKA (51.10%). The stroke rate was significantly lower in DOACs group compared with warfarin group (Relative risk (RR): 0.72; 95% confidence interval (CI): 0.63-0.82; p
%K elderly
%K acute coronary syndrome
%K myocardial infarction
%K vitamin-K antagonist
%K direct oral anticoagulants
%K Stroke prevention
%K Elderly-patients
%K Efficacy
%K Older
%K Risk
%K Dabigatran
%K Apixaban
%K Safety
%K Age
%K Epidemiology
%~